Creative Medical Technology Holdings Inc
Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness. It develops AlloStem (CELZ-201-DD… Read more
Creative Medical Technology Holdings Inc (CELZ) - Net Assets
Latest net assets as of September 2025: $5.59 Million USD
Based on the latest financial reports, Creative Medical Technology Holdings Inc (CELZ) has net assets worth $5.59 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($5.85 Million) and total liabilities ($261.35K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $5.59 Million |
| % of Total Assets | 95.53% |
| Annual Growth Rate | 37.37% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 1550.31 |
Creative Medical Technology Holdings Inc - Net Assets Trend (2006–2024)
This chart illustrates how Creative Medical Technology Holdings Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Creative Medical Technology Holdings Inc (2006–2024)
The table below shows the annual net assets of Creative Medical Technology Holdings Inc from 2006 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $6.34 Million | -38.69% |
| 2023-12-31 | $10.34 Million | -34.80% |
| 2022-12-31 | $15.86 Million | +55.27% |
| 2021-12-31 | $10.22 Million | +125.67% |
| 2020-12-31 | $-39.80 Million | -393.13% |
| 2019-12-31 | $-8.07 Million | -102.06% |
| 2018-12-31 | $-3.99 Million | -78.64% |
| 2017-12-31 | $-2.24 Million | -1317.17% |
| 2016-12-31 | $-157.79K | +14.15% |
| 2015-12-31 | $-183.80K | -20.10% |
| 2014-12-31 | $-153.04K | -22.40% |
| 2013-12-31 | $-125.03K | -27.91% |
| 2012-12-31 | $-97.75K | -35.45% |
| 2011-12-31 | $-72.16K | -50.00% |
| 2010-12-31 | $-48.11K | -55.93% |
| 2009-12-31 | $-30.85K | -4175.69% |
| 2008-12-31 | $757.00 | -97.13% |
| 2007-12-31 | $26.35K | +26.12% |
| 2006-12-31 | $20.89K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Creative Medical Technology Holdings Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 6448255500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.75K | 0.03% |
| Other Components | $70.93 Million | 1118.53% |
| Total Equity | $6.34 Million | 100.00% |
Creative Medical Technology Holdings Inc Competitors by Market Cap
The table below lists competitors of Creative Medical Technology Holdings Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hemogenyx Pharmaceuticals Plc
PINK:HOPHF
|
$4.48 Million |
|
High Sierra Technologies Inc
PINK:HSTI
|
$4.48 Million |
|
Humpuss Intermoda Transportasi
JK:HITS
|
$4.49 Million |
|
PMHS
PINK:PMHS
|
$4.49 Million |
|
Cyclerion Therapeutics Inc
NASDAQ:CYCN
|
$4.48 Million |
|
LOBO EV TECHNOLOGIES LTD. Ordinary shares
NASDAQ:LOBO
|
$4.48 Million |
|
Bakhu Holdings Corp
PINK:BKUH
|
$4.48 Million |
|
CORAL PRODUCTS LS-01
F:0EN
|
$4.48 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Creative Medical Technology Holdings Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 10,343,796 to 6,341,499, a change of -4,002,297 (-38.7%).
- Net loss of 5,493,481 reduced equity.
- Share repurchases of 174,964 reduced equity.
- New share issuances of 1,629,600 increased equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-5.49 Million | -86.63% |
| Share Repurchases | $174.96K | -2.76% |
| Share Issuances | $1.63 Million | +25.7% |
| Other Changes | $36.55K | +0.58% |
| Total Change | $- | -38.69% |
Book Value vs Market Value Analysis
This analysis compares Creative Medical Technology Holdings Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.44x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.00x to 0.44x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-12-31 | $870.50 | $1.88 | x |
| 2007-12-31 | $1097.83 | $1.88 | x |
| 2008-12-31 | $31.54 | $1.88 | x |
| 2009-12-31 | $-1285.54 | $1.88 | x |
| 2010-12-31 | $-2004.54 | $1.88 | x |
| 2011-12-31 | $-3006.83 | $1.88 | x |
| 2012-12-31 | $-4072.88 | $1.88 | x |
| 2013-12-31 | $-5209.63 | $1.88 | x |
| 2014-12-31 | $-6376.79 | $1.88 | x |
| 2015-12-31 | $-7658.50 | $1.88 | x |
| 2016-12-31 | $-1127.08 | $1.88 | x |
| 2017-12-31 | $-14615.51 | $1.88 | x |
| 2018-12-31 | $-3320.56 | $1.88 | x |
| 2019-12-31 | $-3903.05 | $1.88 | x |
| 2020-12-31 | $-686.90 | $1.88 | x |
| 2021-12-31 | $31.45 | $1.88 | x |
| 2022-12-31 | $14.51 | $1.88 | x |
| 2023-12-31 | $7.35 | $1.88 | x |
| 2024-12-31 | $4.28 | $1.88 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Creative Medical Technology Holdings Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -86.63%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -49940.74%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.05x
- Recent ROE (-86.63%) is above the historical average (-368.24%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | 6.57% | 0.00% | 0.00x | 1.40x | $-717.20 |
| 2007 | -36.22% | 0.00% | 0.00x | 1.35x | $-12.18K |
| 2008 | -6953.24% | 0.00% | 0.00x | 1.98x | $-52.71K |
| 2009 | 0.00% | 0.00% | 0.00x | 0.00x | $-28.52K |
| 2010 | 0.00% | 0.00% | 0.00x | 0.00x | $-12.45K |
| 2011 | 0.00% | 0.00% | 0.00x | 0.00x | $-16.84K |
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-15.81K |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-14.78K |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-12.71K |
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-12.38K |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-750.29K |
| 2017 | 0.00% | -55398.08% | 0.02x | 0.00x | $-2.44 Million |
| 2018 | 0.00% | -10977.21% | 0.26x | 0.00x | $-13.26 Million |
| 2019 | 0.00% | -5126.09% | 0.31x | 0.00x | $-7.68 Million |
| 2020 | 0.00% | -22082.21% | 0.23x | 0.00x | $-32.34 Million |
| 2021 | 188.02% | 21892.75% | 0.01x | 1.10x | $18.19 Million |
| 2022 | -63.94% | -11449.26% | 0.00x | 1.21x | $-11.73 Million |
| 2023 | -51.11% | -58739.71% | 0.00x | 1.04x | $-6.32 Million |
| 2024 | -86.63% | -49940.74% | 0.00x | 1.05x | $-6.13 Million |
Industry Comparison
This section compares Creative Medical Technology Holdings Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $177,595,389
- Average return on equity (ROE) among peers: -116.12%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Creative Medical Technology Holdings Inc (CELZ) | $5.59 Million | 6.57% | 0.05x | $4.48 Million |
| Aadi Bioscience Inc (AADI) | $17.44 Million | -122.74% | 0.21x | $17.03 Million |
| America Great Health (AAGH) | $-5.31 Million | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $274.16 Million | -147.88% | 8.55x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $54.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $4.67 Million | -803.57% | 14.26x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $731.78 Million |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $193.84 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $102.67 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $345.85 Million |